Submitted by moderatorj on Thu, 05/10/2012 - 21:45
FDA Warns MS Patients Against Unproven Stent Procedure
Submitted by moderatorj on Thu, 05/10/2012 - 21:45
FDA Warns MS Patients Against Unproven Stent Procedure
Novartis confirms positive benefit-risk profile of Gilenya following CHMP review
The Fly on the Wall
Watchdog says FDA should consider restricting Gilenya
Fierce Pharma
BrainStorm Cell initiates study for MS
The Fly on the Wall
Sanofi faces uphill struggle in MS drug market
Reuters, UK
Biogen Idec: The Patriots of Biotechs
PharmExec